RPG Life Sciences' Q1 FY 2026-27 Quarterly Results

Result Summary

• RPG Life Sciences Ltd reported a 5.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 15.1%.
• Its expenses for the quarter were up by 5.8% QoQ and 14.6% YoY.
• The net profit increased 2.9% QoQ and increased 17.0% YoY.
• The earnings per share (EPS) of RPG Life Sciences Ltd stood at 18.6 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

RPG Life Sciences Ltd is a company involved in the pharmaceutical industry, focusing on the development, manufacture, and marketing of a wide range of pharmaceutical products. The company is known for producing both branded formulations and active pharmaceutical ingredients (APIs). It operates in various therapeutic segments including oncology, cardiovascular, nephrology, and gastroenterology. The company has been active in both domestic and international markets, continually expanding its product portfolio to cater to diverse healthcare needs. As of the latest updates, RPG Life Sciences has been working on enhancing its manufacturing capabilities and investing in research and development to support its growth strategy.

Revenue

In the first quarter of FY27, RPG Life Sciences reported a total income of ₹200.39 crores. This reflects a quarter-over-quarter (QoQ) increase of 5.9% from ₹189.29 crores in Q4FY26. Compared to the first quarter of FY26, where the total income stood at ₹174.15 crores, there is a year-over-year (YoY) increase of 15.1%. This growth indicates a positive trajectory in revenue generation over the past year, showcasing the company's ability to enhance its income streams. The increase in total income is likely attributed to improved sales performance and possibly an expansion in market reach.

Profitability

RPG Life Sciences' profitability metrics for Q1FY27 show a profit before tax (PBT) of ₹41.46 crores, which is a QoQ increase of 3.1% from ₹40.20 crores in Q4FY26. The PBT also shows a YoY growth of 17.0% from ₹35.43 crores in Q1FY26. After accounting for taxes amounting to ₹10.70 crores, the profit after tax (PAT) for Q1FY27 is ₹30.76 crores, reflecting a QoQ increase of 2.9% from ₹29.90 crores in the previous quarter, and a YoY increase of 17.0% from ₹26.29 crores in Q1FY26. The earnings per share (EPS) for this period is noted at ₹18.60, compared to ₹18.08 in Q4FY26, marking a 2.9% increase. The YoY comparison for EPS is not available due to the data provided.

Operating Metrics

The total expenses for RPG Life Sciences in Q1FY27 amount to ₹158.93 crores, up 5.8% QoQ from ₹150.19 crores in Q4FY26, and showing a YoY increase of 14.6% from ₹138.72 crores in Q1FY26. This increase in expenses aligns closely with the growth in total income, suggesting sustained operational activities. The tax expense for the quarter is ₹10.70 crores, which is a 3.9% increase QoQ from ₹10.30 crores in Q4FY26 and a 17.1% increase YoY from ₹9.14 crores in Q1FY26. These figures reflect the company's financial discipline and the impact of increased income on tax obligations. The company’s financial performance in terms of operational metrics displays a consistent pattern of growth in both income and expenses, which is typical for companies expanding their operations and market presence.